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People living within a low socioeconomic status usually 
show a lower health status compared to subjects with high 
socioeconomic status. They are more often sick, diseases 
show a more severe course and life expectancy is redu-
ced. We analyzed this health inequality for skin and atopic 
diseases in a sample of the general European population 
and found quite the contrary: people with high socioeco-
nomic status reported more skin diseases. However, we 
argue that this is an issue of underreporting – in conse-
quence preventive programs should aim at strengthening 
screening approaches for skin diseases in people with low 
socioeconomic status.
The aim of this study was to investigate the associa-
tion between socioeconomic status and the prevalence 
of self-reported skin and atopic diseases in the general 
population of 5 European countries. A random sample 
was drawn from the general population aged 18–74 
years, based on electoral precincts. Socioeconomic 
status was estimated by combining net household 
income with the highest education of respondents. A 
total of 7,904 subjects were included in this analysis. 
The lifetime prevalence of “contact dermatitis” ranged 
from 13.1% (95% confidence interval (95% CI 11.8–
14.4%) in subjects with low socioeconomic status, to 
19.1% (95% CI 17.5–20.8%) in those with high socio­
economic status. In younger subjects skin cancer was 
more prevalent in the middle or high socioeconomic 
status groups compared with the low socioeconomic 
status group (odds ratio 2.4; 95% CI 1.4–4.3); how­
ever, this effect was not found in elderly subjects. The 
lifetime prevalence for at least one atopic disease was 
61.2% (95% CI 59.4–63.0%) in the low and 82.8% 
(95% CI 81.1–84.3%) in the high socioeconomic sta-
tus group. Individuals with middle or high socioeco-
nomic status reported an overall higher prevalence of 
skin and atopic diseases compared with those with low 
socioeconomic status. These findings may reflect diffe-
rences in reporting, which are likely to result in an un-
derdiagnoses, especially for skin cancer in the younger 
age groups with low socioeconomic status.
Key words: socioeconomic status; health inequalities; preva-
lence; skin diseases; European population.
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The association between socioeconomic status (SES) and health state is well known and has been studied 
intensively with widely corresponding results: people 
with low SES (i.e. low income and/or low education), 
in general, have a worse health status compared with 
individuals with middle or high SES (1). A spread in 
life expectancy of up to 20 years can be seen among 
countries as well as within countries between the dif-
ferent socio economic groups (2). Recently, Elgar et al. 
(3) found an increase in health inequalities in adoles-
cents between 2002 and 2010 by analysing time-series 
data from 34 countries. However, for skin diseases the 
situation appears to be different, and there are a couple 
of studies with contradicting results: an early study on 
this topic performed in a UK population showed that 
childhood eczema is more prevalent in higher social 
classes, and this was true for self-reported as well as for 
diagnosed eczema (4). In the UK cancer registry rates 
for all types of skin cancer have been found to be higher 
in individuals with high SES (5, 6). This finding led 
to the conclusion that skin cancer cannot be attributed 
primarily to exposure to sunlight, since individuals with 
low SES are more likely to work in the sun and would 
therefore show higher incidence rates (6). However, in 
other studies occupational exposure to sunlight is clearly 
associated with skin cancer and differences in skin cancer 
mortality cannot be found between SES groups (7). In 
addition, the prevalence of actinic keratosis was found to 
be higher in individuals with low SES in a representative 
Italian sample investigated by trained interviewers using 
a photographic guide (8).
In the Netherlands no associations between SES 
and chronic eczema or psoriasis (9) were diagnosed in 
consecutive samples of patients from general practices. 
Another Dutch study showed that high SES was asso-
ciated with a higher incidence of basal cell carcinoma 
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(BCC) among men (10). This study was based on all 
histologically confirmed BCC registered in the southeast 
Netherlands. A large study focusing on chronic diseases 
performed in 8 European countries found no association 
for skin cancer or any kind of skin disease and SES in 
the self-reported data (11), while allergies were more 
likely to occur in individuals with middle or high SES. 
On the other hand, in a population-based survey in Oslo, 
Norway, a higher prevalence of acne and hand eczema 
was found in households with middle income (12).
For atopic diseases it was argued that higher preva-
lence rates in higher SES groups reflect differences in 
reporting related to language and culture, and would not 
occur in diagnosed cases (13). However, as the studies 
presented above indicate, this explanation does not ac-
count for the findings concerning skin diseases. Overall, 
those results are confusing, and the interpretability of 
existing studies is limited because: (i) data were gained 
in clinical setting(s); and/or (ii) by using small sample 
sizes; and/or (iii) the study was not primarily focusing on 
skin diseases; and/or (iv) data were assessed in a small 
region only. Therefore, the current study analysed the 
impact of SES on the prevalence of skin diseases by using 
data gained in a huge epidemiological survey performed 
in 5 European countries, which was focused on contact 
allergies and skin and atopic diseases.
MATERIALS AND METHODS
This is a post-hoc analysis of data from a prevalence study perfor-
med by the European Dermato-Epidemiology Network (EDEN), 
called the EDEN fragrance study (EFS). The study design of the 
EFS has been published previously (14, 15). In short, EDEN 
conducted a population-based epidemiological survey in 5 Eu-
ropean countries (Sweden, Germany, the Netherlands, Italy and 
Portugal) in order to assess the prevalence of fragrance allergies in 
the general European population (16, 17). A random sample was 
therefore drawn from the general population aged 18–74 years, 
using a stratified, proportional sampling with replacement design. 
This was done by stratifying the data received from the electoral 
precincts of each region by sex and age. If an individual who was 
randomly selected for participation declined to participate or could 
not be reached, a new subject was selected randomly from the 
same strata. This process has been described in detail elsewhere 
(15). Data were assessed during personal interviews performed 
by trained interviewers using a standardized questionnaire. The 
questionnaire addressed information about lifetime prevalence of 
10 common skin diseases (contact dermatitis, atopic dermatitis, 
other eczema, psoriasis, warts, acne, urticaria, skin cancer, leg 
ulcer, and vitiligo) and the atopic diseases rhinitis and allergic 
asthma. In addition, the socioeconomic variables education and 
net household income were assessed. The study was performed 
in accordance with the Declaration of Helsinki and each centre 
received approval from its corresponding ethics committee. 
Indicator variable for socioeconomic status
In this study the education and net household income of respon-
dents were used to compute an indicator variable for SES. For 
each country the income data were split into 6 equal categories, so 
that within a country each category contained the same number of 
respondents. The educational variable was assessed in 6 categories: 
(i) compulsory education or lower, (ii) high school, (iii) vocational 
training, (iv) university training, (v) first-level degree (Bachelor’s 
degree or equivalent) and (vi) second-level degree (Master’s de-
gree or higher). This operationalization equals the definition of 
the International Standard Classification of Education (ISCED) 
(18), where the 2 lowest and 2 highest categories were collapsed. 
The 2 indicator variables were summed to a score ranging from 2 
to 12 and split into 3 groups representing low (score < 6), middle 
(6 ≤ score ≤ 8) and high SES (score > 8). 
Data analyses
The lifetime prevalence was calculated for each disease and is 
reported together with the corresponding 95% confidence interval 
(95% CIs), which were calculated according to the conservative 
Clopper-Pearson method (19). In addition, skin diseases were 
grouped for analysis into “any eczema”’ (contact, atopic or other 
dermatitis), “atopic disease” (atopic dermatitis, rhinitis or asthma) 
and “any skin disease”. The association between SES and each 
disease is described using odds ratios (ORs), calculated by me-
ans of univariate and multivariate logistic regression, the latter 
controlling for age and sex. In order to have an adequate sample 
size for the comparisons, subjects with low SES were compared 
with the rest of the sample (subjects with middle or high SES) in 
all analyses. Because of testing for multiple diseases, significance 
levels were adjusted using the conservative Bonferroni approach 
(20), resulting in a significance level of p ≤ 0.0031 (p ≤ 0.05/16 
diseases).
RESULTS
Overall, 12,370 subjects were included in the study. How-
ever, because the question on income was added after 
the study had already started, complete data on SES are 
available for only 7,904 subjects, and only these were 
eligible for analysis. The sample consists of 4,130 women 
(52.3%); this percentage was slightly lower compared 
with the whole study population reported earlier (53.9%; 
p < 0.001) (14). The median (interquartile range; IQR) 
age was 42 years (28–56) , which was also lower com-
pared with the original population (43 years (29–57); 
p < 0.001). Table I shows that the prevalence for the 
investigated skin and atopic diseases did not differ sig-
nificantly between both populations, only the prevalence 
of contact dermatitis and psoriasis were slightly higher 
in the subsample used for analysis.
Lifetime prevalence of skin and atopic diseases by 
socioeconomic status
Fig. 1 shows that the lifetime prevalence of most skin 
diseases is higher in the high SES group compared with 
the low or middle SES groups. For “other eczema” a 
lifetime prevalence of 10.3% (95% CI 9.2–11.6%) was 
found in individuals with low SES, compared with a 
lifetime prevalence of 18.1% (95% CI 16.5–19.8%) in 
the high SES group. Only for leg ulcer, which has the 
lowest lifetime prevalence of the skin diseases investi-
gated (0.6%; 95% CI 0.4–0.8%) the lifetime prevalence 
in the group with low SES (0.7%; 95% CI 0.4–1.1%) 
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(0.4%; 95% CI 0.2–0.8%). The prevalence of having any 
skin disease was 61.2% (95% CI 59.4–63.0%) in people 
with low SES and 82.8% (95% CI 81.1–84.3%) in the 
group with high SES. The detailed prevalence data for 
all skin and atopic diseases investigated in this study for 
each SES group is shown in Table II.
Univariate odds ratios for socioeconomic status in 
different groups
Nearly all calculated univariate ORs indicated a higher 
prevalence for skin and atopic diseases in individuals 
with middle or high SES compared with those with low 
SES. For warts, an OR of 1.87 (95% CI 1.7–2.1) was 
found, indicating warts to be more prevalent in subjects 
with middle or high SES. The OR of having at least one 
of the reported skin diseases in a lifetime was 2.18 (95% 
CI 1.97–2.41). Only for leg ulcer was there an OR that 
indicated a higher prevalence in subjects with low SES 
(OR 0.65; OR 0.36–1.17), but this effect was not signi-
ficant. In Table III it can be seen, that by considering 
only the group of elderly subjects (60–74 years) the OR 
for leg ulcer indicated a lower prevalence in middle or 
high SES subject (OR 0.41; 95% CI 0.18–0.93). The OR 
for rhinitis (OR 2.19; 95% CI 1.57–3.04) also indicated 
rhinitis to be more prevalent in subjects with middle or 
high SES. 
Overall the ORs in elderly age groups were slightly 
higher compared with the younger age groups. How-
ever, the OR for skin cancer was significant only in the 
younger age group (OR 2.4; 95% CI 1.35–4.28). When 
comparing the ORs for men and women it can be seen 
Table I. Characteristics of the analysed sample compared with the 
total sample of the general European population





n (%) 95% CI n (%) 95% CI
Sex*
  Women 4,130 (52.3) 51.2–53.4 6,669 (53.9) 53.0–54.8
  Men 3,770 (47.7) 46.6–48.8 5,701 (46.1) 45.2–47.0
Age in years, median (IQR)* 42 (28–56) 43 (29–57)
Contact dermatitis* 1,273 (16.1) 15.3–16.9 1,854 (15.0) 14.4–15.6
Atopic dermatitis 608 (7.8) 7.2–8.4 898 (7.9) 7.4–8.4
Other eczema 1,066 (13.7) 12.9–14.5 1,624 (14.2) 13.5–14.8
Psoriasis* 438 (5.6) 5.1–6.1 590 (5.2) 4.8–5.7
Warts 3,256 (41.9) 40.8–43.0 4,897 (41.3) 40.4–42.2
Acne 1,494 (19.3) 18.4–20.2 2,202 (19.2) 18.5–20.0
Urticaria 710 (9.2) 8.6–9.9 1,040 (9.2) 8.7–9.7
Skin cancer 219 (2.8) 2.4–3.2 292 (2.6) 2.3–2.9
Leg ulcer 44 (0.6) 0.4–0.8 78 (0.7) 0.5–0.9
Vitiligo 138 (1.8) 1.5–2.1 213 (1.9) 1.6–2.2
Allergic rhinitis 1,575 (20.3) 19.4–21.2 2,347 (20.4) 19.7–21.1
Allergic asthma 610 (7.9) 7.3–8.5 925 (8.1) 7.6–8.6
Other skin diseases* 829 (10.7) 10.0–11.4 1,281 (11.3) 10.7–11.9
*Differences significant (Bonferroni adjusted p < 0.003).


























Fig. 1. Lifetime prevalence of skin diseases by socioeconomic status.









n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI
Contact dermatitis 364 (13.1) 11.8–14.4 489 (16.7) 15.4–18.2 420 (19.1) 17.5–20.8 1,273 (16.1) 15.3–16.9
Atopic dermatitis 170 (6.2) 5.4–7.2 237 (8.3)   7.3–9.3 201 (9.2)   8.0–10.5 608 (7.8)   7.2–8.4
Other dermatitis 282 (10.3) 9.2–11.6 391 (13.7) 12.4–15.0 393 (18.1) 16.5–19.8 1,066 (13.7) 13.0–14.5
Psoriasis 128 (4.7) 3.9–5.6 166 (5.8)   5.0–6.7 144 (6.6)   5.6–7.7 438 (5.6)   5.1–6.2
Warts 880 (32.2) 30.5–34.0 1,243 (43.4) 41.5–45.2 1,133 (52.1) 49.9–54.2 3,256 (41.9) 40.8–43.0
Acne 403 (14.8) 13.5–16.2 560 (19.6) 18.1–21.1 531 (24.4) 22.6–26.3 1,494 (19.3) 18.4–20.2
Urticaria 202 (7.4) 6.5–8.5 268 (9.4)   8.3–10.5 240 (11.0) 9.7–12.4 710 (9.2) 8.5–9.8
Skin cancer   68 (2.5) 1.9–3.2   77 (2.7)   2.1–3.4   74 (3.4) 2.7–4.3 219 (2.8) 2.5–3.2
Leg ulcer   20 (0.7) 0.5–1.1   15 (0.5)   0.3–0.9     9 (0.4) 0.2–0.8   44 (0.6) 0.4–0.8
Vitiligo   44 (1.6) 1.2–2.2   47 (1.6)   1.2–2.2   47 (2.2) 1.6–2.9 138 (1.8) 1.5–2.1
Rhinitis 426 (15.6) 14.3–17.1 569 (19.8) 18.4–21.4 580 (26.6) 24.8–28.5 1,575 (20.3) 19.4–21.2
Asthma 192 (7.1) 6.1–8.1 225 (7.9)   6.9–8.9 193 (8.9)   7.7–10.1 610 (7.9)   7.3–8.5
Other skin diseases 701 (25.1) 23.5–26.8 943 (32.3) 30.6–34.0 848 (38.6) 36.6–40.7 2,492 (31.5) 30.5–32.6
Any skin disease 611 (22.3) 20.8–23.9 782 (27.2) 25.6–28.9 744 (34.1) 32.1–36.1 2,137 (27.4) 26.4–28.4
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that OR in men are mostly higher compared with women; 
only for contact dermatitis and atopic dermatitis are the 
ORs higher in women.
Country-specific multivariate odds ratios for 
socioeconomic status
At the country level and by controlling for age and sex 
most ORs were smaller and no longer significant. In 
Germany and Italy no association between SES and one 
of the reported skin diseases was found after applying 
Bonferroni correction of the significance level (Table 
IV). The most associations were seen in Portugal; here 
the ORs for SES in other dermatitis (OR 3.7; 95% CI 
2.32–5.93), rhinitis (OR 3.1; 95% CI 1.87–4.97), other 
skin diseases (OR 2.3; 95% CI 1.60–3.43) as well as in 
the groups for any eczema (OR 1.8; 95% CI 1.32–2.52), 
atopic disease (OR 2.3; 95% CI 1.55–3.30) and any skin 
disease (OR 1.9; 95% CI 1.44–2.61) were significant. All 
ORs in Portugal indicated skin and atopic diseases to be 
more prevalent in individuals with middle or high SES. 
In Sweden and the Netherlands there was only one 
significant association that showed the opposite re-
sult compared with the results reported to date: in the 
Netherlands there was a significant OR of 0.1 (95% CI 
0.05–0.41) for the effect of SES in skin cancer, indicating 
skin cancer to be more prevalent in individuals with low 
SES. Similar results were found in Sweden, where leg 
ulcers were more likely to occur in individuals with low 
SES (OR 0.19; 95% CI 0.06–0.58). In Germany and Italy 
no significant associations were found between SES and 
the burden of skin and atopic diseases.
DISCUSSION
Overall, the association between SES and dermatologi-
cal and atopic conditions appears to contrast with that 
of other diseases: people with high SES report a higher 
lifetime prevalence than those with low SES. This asso-
ciation seems to be more relevant in elderly subjects and 
in men. However, for skin cancer, health inequality was 
found only in the younger age group (showhing higher 
















Contact dermatitis 1.14 (0.94–1.38) 1.12 (0.74–1.70) 1.18 (0.73–1.92) 1.06 (0.68–1.67) 1.02 (0.72–1.45)
Atopic dermatitis 1.14 (0.88–1.49) 1.28 (0.74–2.20) 1.11 (0.60–2.05) 1.12 (0.59–2.12) 1.84 (1.15–2.95)
Other dermatitis 1.13 (0.90–1.42) 1.30 (0.63–2.69) 0.91 (0.63–1.30) 3.71 (2.32–5.93) 1.20 (0.89–1.63)
Psoriasis 0.87 (0.64–1.16) 1.37 (0.67–2.79) 1.30 (0.37–4.57) 1.44 (0.47–4.38) 1.21 (0.80–1.83)
Warts 1.16 (0.98–1.38) 1.26 (0.80–1.97) 1.19 (0.86–1.64) 1.03 (0.76–1.39) 1.04 (0.81–1.34)
Acne 1.12 (0.94–1.35) 1.57 (0.98–2.50) 1.02 (0.68–1.52) 1.60 (1.08–2.38) 1.01 (0.72–1.42)
Urticaria 0.99 (0.77–1.27) 1.14 (0.60–2.16) 1.07 (0.59–1.96) 1.88 (0.86–4.10) 1.23 (0.87–1.74)
Skin cancer 1.45 (0.81–2.60) 2.62 (0.65–10.54) 0.14 (0.05–0.41) 3.45 (0.35–34.03) 0.89 (0.58–1.35)
Leg ulcer 1.63 (0.36–7.36) n.a.* 0.28 (0.07–1.09) n.a.* 0.19 (0.06–0.58)
Vitiligo 1.12 (0.64–1.97) 0.95 (0.21–4.27) 0.42 (0.17–1.04) 0.82 (0.13–5.05) 0.75 (0.35–1.59)
Rhinitis 1.15 (0.96–1.39) 0.88 (0.53–1.46) 0.82 (0.58–1.16) 3.05 (1.87–4.97) 1.09 (0.83–1.45)
Asthma 0.98 (0.74–1.29) 0.71 (0.38–1.33) 0.67 (0.41–1.09) 2.16 (1.07–4.37) 0.99 (0.68–1.44)
Other skin diseases 1.33 (1.03–1.72) 1.74 (0.70–4.37) 1.78 (1.02–3.10) 2.35 (1.60–3.43) 1.13 (0.77–1.65)
Any eczema 1.21 (1.02–1.43) 1.20 (0.86–1.68) 0.96 (0.70–1.31) 1.83 (1.32–2.52) 1.21 (0.95–1.54)
Atopic disease 1.11 (0.94–1.32) 1.02 (0.70–1.48) 0.78 (0.57–1.07) 2.26 (1.55–3.30) 1.16 (0.91–1.47)
Any skin diseases 1.18 (0.88–1.58) 1.29 (1.01–1.65) 0.93 (0.57–1.51) 1.94 (1.44–2.61) 1.19 (0.96–1.47)
Bold ORs are significant (Bonferroni adjusted p < 0.003) *not applicable; no leg ulcers were reported in Italy or Spain. CI: confidence interval.
















Contact dermatitis 1.44 (1.26–1.64) 1.39 (1.11–1.75) 1.52 (1.29–1.79) 1.33 (1.16–1.54) 1.81 (1.29–2.53)
Atopic dermatitis 1.43 (1.19–1.72) 1.44 (1.05–1.98) 1.46 (1.17–1.84) 1.36 (1.12–1.65) 1.46 (0.84–2.52)
Other dermatitis 1.60 (1.38–1.85) 2.04 (1.60–2.59) 1.39 (1.15–1.67) 1.59 (1.35–1.88) 1.56 (1.13–2.14)
Psoriasis 1.33 (1.08–1.64) 1.46 (1.08–1.98) 1.21 (0.90–1.62) 1.37 (1.06–1.76) 1.36 (0.91–2.03)
Warts 1.87 (1.70–2.07) 2.08 (1.80–2.41) 1.72 (1.51–1.97) 1.80 (1.62–2.01) 1.94 (1.56–2.43)
Acne 1.59 (1.40–1.80) 1.69 (1.40–2.04) 1.52 (1.29–1.80) 1.47 (1.28–1.68) 1.94 (1.38–2.74)
Urticaria 1.40 (1.18–1.66) 1.72 (1.24–2.39) 1.33 (1.09–1.63) 1.47 (1.20–1.79) 1.27 (0.91–1.78)
Skin cancer 1.21 (0.90–1.61) 1.22 (0.80–1.85) 1.18 (0.79–1.77) 2.40 (1.35–4.28) 1.17 (0.81–1.67)
Leg ulcer 0.65 (0.36–1.17) 0.84 (0.35–2.03) 0.51 (0.23–1.17) 1.86 (0.62–5.62) 0.41 (0.18–0.93)
Vitiligo 1.16 (0.81–1.66) 1.16 (0.69–1.95) 1.16 (0.70–1.91) 1.31 (0.85–2.01) 0.88 (0.44–1.77)
Rhinitis 1.59 (1.41–1.80) 1.78 (1.48–2.14) 1.46 (1.24–1.72) 1.45 (1.27–1.65) 2.19 (1.57–3.04)
Asthma 1.19 (1.00–1.43) 1.46 (1.10–1.95) 1.05 (0.84–1.32) 1.22 (1.00–1.49) 1.06 (0.72–1.57)
Other skin diseases 1.72 (1.46–2.03) 1.63 (1.28–2.09) 1.81 (1.45–2.26) 1.86 (1.53–2.25) 1.41 (1.01–1.95)
Any skin disease 2.18 (1.97–2.41) 2.29 (1.99–2.65) 2.11 (1.83–2.43) 2.16 (1.92–2.42) 2.08 (1.69–2.58)
Atopic disease 1.50 (1.35–1.68) 1.70 (1.44–2.00) 1.38 (1.20–1.60) 1.43 (1.27–1.61) 1.63 (1.25–2.12)
Any eczema 1.60 (1.45–1.78) 1.74 (1.48–2.06) 1.58 (1.38–1.81) 1.53 (1.37–1.72) 1.73 (1.35–2.20)
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rates in the group with high SES) and in the Netherlands 
this association was reversed. The association between 
leg ulcers and SES also indicates that they were more 
prevalent in individuals with low SES.
Strengths and limitations
While most studies on this topic were perfomed using 
data from consecutive clinical patients we assessed the 
prevalence of skin and atopic diseases in a sample of the 
general population. This is a strength of our study, since 
people with high SES are likely to have better access to 
the health system and might therefore be overrepresented 
in a clinical setting. Other barriers may also exist; for 
example, in Germany children with low SES are less 
likely to visit a physician (21), even though the German 
health system provides ubiquitous access to healthcare 
through its mandatory health insurance. The discrepan-
cies in access and behaviour between low and high SES 
groups do not affect the data of the representative sample 
of the European general population analysed in our study. 
Although the response rate of the EDEN fragrance study 
was quite low, the study sample was compared with other 
data sources from the general population and found to 
be relatively comparable (14).
Due to organizational issues we were only able to 
analysis a subsample of the total study population, 
which deviated slightly from the sample of the general 
population in terms of age, sex and lifetime prevalence 
of contact dermatitis and psoriasis. Nevertheless, we 
consider these deviations too small to have a relevant ef-
fect on the association between SES and skin diseases as 
presented in this paper. A further limitation of this study 
is that information about the prevalence of skin diseases 
was collected using self-reports from the participants. 
People with high SES might be: (i) more aware; (ii) bet-
ter informed about potential skin diseases; or (iii) paying 
more attention to dermatological problems and therefore 
more likely to report them. Finally, the current study did 
not assess severity. There are some studies indicating that 
the dermatological and atopic conditions are more severe 
in individuals with low SES (22, 23).
Comparison with other studies
While in developing countries skin diseases are clearly 
an indicator for poverty and low SES (24, 25) this is not 
true for the western European countries investigated in 
this study. An increased risk was found in the higher SES 
group for nearly all skin diseases investigated, excluding 
only psoriasis, skin cancer and leg ulcers. In particular, 
the results regarding skin cancer, which showed only 
a positive association in the younger groups, and even 
showed an inverse association in the Dutch population, 
are not in agreement with earlier findings (5, 6). A Dutch 
study performed in the southeast Netherlands showed 
an association between high SES and an increased risk 
of skin cancer among men (10). In this study, only the 
incidence of BCC was investigated, while in the current 
Dutch population, in the northeast of the Netherlands, 
we investigated skin cancer in general. The 2 populations 
in the Netherlands might differ in terms of UV exposure 
(outdoor activities), which is the main risk factor for skin 
cancer. Considering the fact that lower survival rates in 
skin cancer patients with low SES have been reported 
(26, 27), it appears likely that skin cancer is often under-
diagnosed or diagnosed later in individuals with low SES, 
leading to a worse prognosis in these patients. Therefore, 
future intervention programmes for skin cancer should 
focus on subjects with low SES. While the effect of SES 
on the prevalence of common chronic diseases (including 
skin diseases) in the general European population was 
found to be smaller in the elderly population (11), we 
found a slightly higher OR in the elderly population.
Future studies and conclusion
Future studies should examine why effects of SES on 
skin cancer and leg ulcer show the opposite direction 
in Sweden and the Netherlands compared to the other 
countries. Future studies should also explore the reason 
why health inequality seems to be less intense in tose two 
countries. It would be interesting to investigate whether 
the same mechanism that leads to a generally worse state 
of health in people with low SES (e.g. the extent of in-
come inequality within a country (28)), leads to a worse 
skin morbidity in people with high SES. Future studies 
on the effects of SES on skin diseases should assess the 
point prevalence of skin diseases by applying a stan-
dardized physical examination, performed by a trained 
dermatologist, including a severity rating of diseases. It 
is evident that there are discrepancies in health equality 
concerning skin and atopic diseases between countries 
within the European community; scientists from all over 
Europe should work together to reduce these gaps. 
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